Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

Blood. 2021 Nov 25;138(21):2138-2142. doi: 10.1182/blood.2021012392.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Immunotherapy, Adoptive
  • Infant
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Receptors, Antigen, T-Cell / therapeutic use*
  • Retrospective Studies
  • Treatment Outcome
  • Young Adult

Substances

  • Antineoplastic Agents, Immunological
  • Receptors, Antigen, T-Cell
  • tisagenlecleucel